Biogen MA Inc.
Biogen MA Inc., commonly referred to as Biogen, is a leading biotechnology company headquartered in the United States. Founded in 1978, Biogen has established itself as a pioneer in the development of therapies for neurological diseases, with a strong focus on multiple sclerosis, spinal muscular atrophy, and Alzheimer’s disease.
With major operational regions across North America, Europe, and Asia, Biogen is renowned for its innovative products, including the first approved treatment for spinal muscular atrophy. The company’s commitment to research and development has positioned it as a key player in the biotechnology industry, achieving significant milestones such as the launch of groundbreaking therapies that address unmet medical needs. Biogen's dedication to advancing neuroscience continues to drive its market leadership and influence in the biopharmaceutical sector.
+41 vs industry average
Biogen MA Inc.’s score of 79 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Biogen MA Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for Biogen MA Inc. yet.
Biogen MA Inc.'s reported carbon emissions
Biogen MA Inc., headquartered in the US, currently does not report specific carbon emissions data for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Biogen Inc., which may influence its climate commitments and reporting practices.
While no specific reduction targets or achievements are available for Biogen MA Inc., it is important to note that the company inherits its climate initiatives from its parent organisation, Biogen Inc. This includes participation in various sustainability initiatives such as the Science Based Targets initiative (SBTi), CDP, and RE100, all of which are cascaded from Biogen Inc. at a corporate family level.
Biogen Inc. has made commitments to reduce its carbon footprint and enhance sustainability practices, although specific targets for Biogen MA Inc. are not detailed. The absence of direct emissions data suggests that the company may still be in the process of establishing its own reporting framework or may rely on aggregated data from its parent company.
In summary, while Biogen MA Inc. does not currently provide specific emissions data or reduction targets, it is aligned with the broader sustainability efforts of Biogen Inc., which are aimed at addressing climate change and reducing overall carbon emissions.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Biogen MA Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Biogen MA Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Inherited from Biogen Inc.
Carbon Disclosure Project
Inherited from Biogen Inc.
The Climate Pledge
UN Global Compact Climate Champions initiative
Inherited from Biogen Inc.
RE 100
Inherited from Biogen Inc.
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Biogen MA Inc.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project